CEACAM5 and lung carcinoma: In a recent study, a serum biomarker panel including Pro-SFTPB, CA125, Cyfra21‐1, and CEA was demonstrated to be efficiently predicting the short-term (6~12 months) lung cancer risk in an ever-smoking patient population 11.